3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium ... 13 antibody for atopic dermatitis that offers less frequent dosing than its two predecessors in the class, Sanofi/Regeneron's ...

Cobenfy sales in the fourth quarter were approximately ... but there are questions around the tolerability and the BID dosing. So just interested to know if there's any early signs of sort of ...

Cobenfy is also in phase 3 clinical testing ... currently in two phase 2 studies. It offers once-daily dosing, versus twice-daily with BMS' drug and, according to some assessments, could be ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Objective: To determine ...

Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...

Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to ...

The trial initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investigational Mim8 before giving participants the option to ...